CYCLO THERAPEUTICS INC (CYTH) Stock Fundamental Analysis

NASDAQ:CYTH • US23254X2018

0.7206 USD
+0.01 (+1.39%)
At close: Mar 25, 2025
0.7199 USD
0 (-0.1%)
After Hours: 3/25/2025, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CYTH. CYTH was compared to 520 industry peers in the Biotechnology industry. Both the profitability and financial health of CYTH have multiple concerns. While showing a medium growth rate, CYTH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CYTH had negative earnings in the past year.
  • In the past year CYTH has reported a negative cash flow from operations.
  • CYTH had negative earnings in each of the past 5 years.
  • CYTH had a negative operating cash flow in each of the past 5 years.
CYTH Yearly Net Income VS EBIT VS OCF VS FCFCYTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

  • The Return On Assets of CYTH (-472.02%) is worse than 96.65% of its industry peers.
Industry RankSector Rank
ROA -472.02%
ROE N/A
ROIC N/A
ROA(3y)-196.91%
ROA(5y)-167.39%
ROE(3y)-876.42%
ROE(5y)-703.18%
ROIC(3y)N/A
ROIC(5y)N/A
CYTH Yearly ROA, ROE, ROICCYTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

1.3 Margins

  • CYTH has a Gross Margin of 91.24%. This is amongst the best in the industry. CYTH outperforms 91.90% of its industry peers.
  • In the last couple of years the Gross Margin of CYTH has remained more or less at the same level.
  • CYTH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.39%
CYTH Yearly Profit, Operating, Gross MarginsCYTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • CYTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CYTH has more shares outstanding
  • There is no outstanding debt for CYTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYTH Yearly Shares OutstandingCYTH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CYTH Yearly Total Debt VS Total AssetsCYTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

  • CYTH has an Altman-Z score of -45.56. This is a bad value and indicates that CYTH is not financially healthy and even has some risk of bankruptcy.
  • CYTH's Altman-Z score of -45.56 is on the low side compared to the rest of the industry. CYTH is outperformed by 93.13% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -45.56
ROIC/WACCN/A
WACC10.15%
CYTH Yearly LT Debt VS Equity VS FCFCYTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

  • A Current Ratio of 0.17 indicates that CYTH may have some problems paying its short term obligations.
  • CYTH's Current ratio of 0.17 is on the low side compared to the rest of the industry. CYTH is outperformed by 96.48% of its industry peers.
  • A Quick Ratio of 0.16 indicates that CYTH may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.16, CYTH is doing worse than 96.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.17
Quick Ratio 0.16
CYTH Yearly Current Assets VS Current LiabilitesCYTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.87% over the past year.
  • Looking at the last year, CYTH shows a decrease in Revenue. The Revenue has decreased by -8.86% in the last year.
  • The Revenue has been growing slightly by 1.28% on average over the past years.
EPS 1Y (TTM)44.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.34%
Revenue 1Y (TTM)-8.86%
Revenue growth 3Y6.15%
Revenue growth 5Y1.28%
Sales Q2Q%-52.98%

3.2 Future

  • Based on estimates for the next years, CYTH will show a very strong growth in Earnings Per Share. The EPS will grow by 20.87% on average per year.
  • CYTH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 106.48% yearly.
EPS Next Y56.84%
EPS Next 2Y25.49%
EPS Next 3Y20.87%
EPS Next 5YN/A
Revenue Next Year-41.47%
Revenue Next 2Y-14.64%
Revenue Next 3Y106.48%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CYTH Yearly Revenue VS EstimatesCYTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M
CYTH Yearly EPS VS EstimatesCYTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • CYTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYTH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTH Price Earnings VS Forward Price EarningsCYTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTH Per share dataCYTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • CYTH's earnings are expected to grow with 20.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.49%
EPS Next 3Y20.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CYTH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CYCLO THERAPEUTICS INC

NASDAQ:CYTH (3/25/2025, 8:00:01 PM)

After market: 0.7199 0 (-0.1%)

0.7206

+0.01 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25
Earnings (Next)05-13
Inst Owners11.45%
Inst Owner Change0%
Ins Owners8.13%
Ins Owner Change0%
Market Cap23.72M
Revenue(TTM)870.80K
Net Income(TTM)-24.80M
Analysts77.78
Price Target0.97 (34.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.89%
Min EPS beat(2)-68.96%
Max EPS beat(2)-32.83%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-38.61%
Min Revenue beat(2)-54.92%
Max Revenue beat(2)-22.3%
Revenue beat(4)0
Avg Revenue beat(4)-39.05%
Min Revenue beat(4)-54.92%
Max Revenue beat(4)-22.3%
Revenue beat(8)1
Avg Revenue beat(8)-43.22%
Revenue beat(12)2
Avg Revenue beat(12)-33.37%
Revenue beat(16)3
Avg Revenue beat(16)-29.66%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.03
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -472.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.24%
FCFM N/A
ROA(3y)-196.91%
ROA(5y)-167.39%
ROE(3y)-876.42%
ROE(5y)-703.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.39%
F-Score3
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.17
Quick Ratio 0.16
Altman-Z -45.56
F-Score3
WACC10.15%
ROIC/WACCN/A
Cap/Depr(3y)70.81%
Cap/Depr(5y)142.49%
Cap/Sales(3y)0.98%
Cap/Sales(5y)1.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.34%
EPS Next Y56.84%
EPS Next 2Y25.49%
EPS Next 3Y20.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.86%
Revenue growth 3Y6.15%
Revenue growth 5Y1.28%
Sales Q2Q%-52.98%
Revenue Next Year-41.47%
Revenue Next 2Y-14.64%
Revenue Next 3Y106.48%
Revenue Next 5YN/A
EBIT growth 1Y-27.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.22%
OCF growth 3YN/A
OCF growth 5YN/A

CYCLO THERAPEUTICS INC / CYTH FAQ

What is the ChartMill fundamental rating of CYCLO THERAPEUTICS INC (CYTH) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CYTH.


What is the valuation status for CYTH stock?

ChartMill assigns a valuation rating of 1 / 10 to CYCLO THERAPEUTICS INC (CYTH). This can be considered as Overvalued.


How profitable is CYCLO THERAPEUTICS INC (CYTH) stock?

CYCLO THERAPEUTICS INC (CYTH) has a profitability rating of 1 / 10.


What is the expected EPS growth for CYCLO THERAPEUTICS INC (CYTH) stock?

The Earnings per Share (EPS) of CYCLO THERAPEUTICS INC (CYTH) is expected to grow by 56.84% in the next year.